| [1] | Koeberle D, Saletti P, Borner M, et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine:a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research[J]. J Clin Oncol, 2008,26(22):3702-3708. |
| [2] | Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study[J]. J Clin Oncol,2010,28:4581-4586. |
| [3] | Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies[J]. J Clin Oncol, 2010, 28: 3531-3540 |
| [4] | Van Cutsem E,Köhne CH,Hitre E,et al.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J].N Engl J Med,2009,360 (14):1408-1417. |
| [5] | Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study[J].Lancet Oncol, 2010,11(12):1142-1148. |
| [6] | Rubovszky G,Lang I,Ganofszky E,et al.Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study[J].Eur J Cancer,2013,49(18): 3806-3812. |
| [7] | Borbath I,Ceratti A,Verslype C,et al.Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology[J].Ann Oncol,2013,24(11): 2824-2829. |
| [8] | Paule B, Bralet M, Herelle M, et al.Cetuximab plus gemcitabine/oxaliplatin (GEMOX) for patients with unresectable/recurrent intrahepatic cholangiocarcinoma refractory to GEMOX[J].Oncology,2007,72(1-2):105-110. |